

INTERNAL MEDICINE ALERT[®]

A twice-monthly update of developments in internal and family medicine

CUMULATIVE INDEX Volume 30 January 2008—December 2008

A

- abdominal aortic aneurysms**
screening, 10:76
- acne vulgaris**
benzoyl peroxide, 23:183
clindamycin, 23:183
- acromegaly**, lanreotide, 7:52-54
- acute coronary syndromes**
clopidogrel, 6:48
- aggression**, dementia, 9:71
- agitation**, dementia, 9:71
- allergic rhinitis**, ciclesonide, 1:4-5
- Alzheimer's disease**
cognitive impairment, 16:122-123
disruptive behavior, 6:43-44
progression, 16:122-123
- androgen deprivation therapy**
prostate cancer, 16:128
- antibiotics**
sinusitis, 9:71
urinary tract infection, 3:17-19
- anticoagulant therapy**
pulmonary thromboembolism, 3:19-20
venous thromboembolism, 3:19-20
- antidepressants**
clinical guidelines, 24:189-190
publication bias, 5:39
Type 2 diabetes, 8:64
- antipsychotics**
elderly, 11:83-85
pneumonia, 11:83-85
- anxiety**, duloxetine, 13:101-102
- arthroscopy**
knee osteoarthritis, 19:144-146
- atrial fibrillation**
coronary heart failure, 16:128

B

- back pain**
lifting equipment, 6:42-43
lifting training, 6:42-43

- NSAIDs, 1:7
spinal manipulation, 1:7
- benign prostatic hyperplasia**
dutasteride, 14:110-111
silodosin (Rapaflo[™]), 24:190-191
tamsulosin, 14:110-111
- benzoyl peroxide**, acne vulgaris, 23:183
- beta-blockers**, COPD, 15:113-114
- beta-cell function**
insulin, 22:176
Type 2 diabetes, 13:103
- bipolar disease**, diagnostic accuracy, 15:119
- body composition**, testosterone, 18:144
- bone mineral density**
glucocorticoid therapy, 2:16
testosterone, 18:144
- breast cancer**
hormone replacement therapy, 10:75-76
- breast size**
predictor of Type 2 diabetes, 7:49-50

C

- caffeine**
cancer, 16:123-124
cardiovascular disease, 16:123-124
mortality, 16:123-124
- calcium supplementation**
cardiovascular disease, 4:25-26
patient education, 16:121-122
physician counseling, 16:121-122
- cancer**
caffeine, 16:123-124
elevated white blood cell count, 1:1-2
ezetimibe, 23:179-181
radiation exposure, 5:35-36
screening, 1:1-2
undiagnosed, 22:171-172
venous thromboembolism, 22:171-172
- cardiac catheterization**
gender, 18:138-139
STEMI, 4:27-28

cardiovascular disease

- caffeine, 16:123-124
- calcium supplementation, 4:25-26
- carotid bruit, 12:96
- carotid intima medial thickness, 10:80
- coronary artery calcium scoring, 10:80
- erectile dysfunction, 7:55
- fatigue, 14:108-109
- folic acid, 13:100-101; 12:96
- homocysteine, 20:159; 13:100-101; 12:96
- hormone replacement therapy, 10:75-76
- lifestyle modification, 15:115-117
- mortality, 12:92-94
- obesity, 15:115-117; 12:92-94
- pulmonary cackles, 14:105-106
- risk stratification, 10:80
- sleep apnea, 2:9-11
- Type 2 diabetes, 22:176; 20:156-159; 10:80
- uric acid, 24:192
- vitamin B therapy, 13:100-101; 12:96
- vitamin D, 21:161-163
- vitamin E, 1:7
- women, 12:92-94
- carotid bruit**, cardiovascular disease, 12:96
- carotid intima medial thickness**
Type 2 diabetes, 10:80
- chest X-ray**, frequency in ICU, 6:44-45
- chorea**, tetrabenazine, 19:149-150
- chronic heart failure**
polyunsaturated fatty acids, 21:167
- chronic lymphocytic leukemia**
bendamustine, 8:62-63
- chronic obstructive pulmonary disease**
beta-blockers, 15:113-114
fluticasone, 21:153-155; 18:144
formoterol, 18:144
salmeterol, 21:153-155; 18:144
tiotropium, 21:163-165; 18:144
- clindamycin**, acne vulgaris, 23:183
- clinical guidelines**
PSA screening, 17:129-131

- second-generation antidepressants, 24:189-190
- Type 2 diabetes, 23:177-178
- clopidogrel**
- acute coronary syndromes, 6:48
 - atrial fibrillation, 5:36-37
 - cessation, 6:48
 - vs warfarin, 5:36-37
- cognitive function**
- Alzheimer's disease, 16:122-123
 - coronary artery disease, 13:97-98
 - elderly, 11:82-83
 - exercise, 19:151
 - impairment, 11:82-83
 - prevalence, 11:82-83
- colon cancer**
- nonpolypoid colorectal neoplasms, 8:64
- colonoscopy**
- computed tomography, 20:155-156
 - ethnic differences, 22:176
 - frequency, 21:167
 - lubiprostone, 22:173
 - preparation, 22:173
- communication**
- end-of-life care, 22:169-171
 - patient-physician, 22:169-171
- constipation**
- methylnaltrexone, 14:112
 - prucalopride, 14:112
- continuous positive airway pressure**
- metabolic syndrome, 24:192
 - sleep apnea, 24:192; 2:9-11
- contraception**, middle-aged women, 10:80
- corn**, diverticular disease, 17:131-132
- coronary artery disease**
- cognitive function, 13:97-98
 - lifestyle modification, 18:141-143
 - managing stable disease, 18:141-142
 - percutaneous coronary intervention, 18:141-143
 - thiazolidinedione, 9:71
- coronary heart disease**, DASH diet, 9:66-68
- coronary heart failure**
- atrial fibrillation, 16:128
- coronary ischemia**
- percutaneous coronary intervention, 24:192
- cough**, honey, 8:61
- C-reactive protein**, genotypes, 23:183
- Crohn's disease**
- certolizumab, 10:78-79
 - omega-3 fatty acids, 11:81-82
- CT scans**
- radiation exposure, 5:35-36
- culture**
- patient-physician relationship, 19:147-148
- D**
- DASH diet**
- coronary heart disease, 9:66-68
 - stroke, 9:66-68
- dementia**
- aggression, 9:71
 - agitation, 9:71
 - survival times, 5:34-35
- depression**
- desvenlafaxine, 6:46-47
 - duloxetine, 13:101-102
 - Type 2 diabetes, 17:132-133
- detrusor overactivity**, reflexology, 7:51-52
- diabetes**
- comorbidities, 2:13-14
 - fracture risk, 12:96
 - glucose metrics, 17:135
 - rosiglitazone, 12:96
- diabetic peripheral neuropathic pain**
- aliskiren, 13:103
 - duloxetine, 13:101-102
 - linolenic acid, 4:32
 - losartan, 13:103
 - pregabalin, 16:128
- diabetic retinopathy**, fenofibrate, 2:16
- diverticular disease**
- corn, 17:131-132
 - nuts, 17:131-132
 - popcorn, 17:131-132
 - seeds, 17:131-132
- dyslipidemia**
- ezetimibe, 10:73-75
 - fish oils, 18:139-140
 - lifestyle modification, 18:139-140
 - red yeast rice, 18:139-140
 - statins, 18:139-140
- E**
- elderly**
- antipsychotics, 11:83-85
 - cognitive impairment, 11:82-83
 - fatigue, 24:188-189
 - hypertension, 11:87
 - mortality, 24:188-189
 - pneumonia, 11:83-85
- electronic health records**
- physician perception, 14:106-108
 - usage statistics, 14:106-108
- emphysema**
- lung cancer, 24:185-186
 - smoking, 24:185-186
- end-of-life care**
- caregiver bereavement, 22:169-171
 - caregiver support, 22:169-171
 - hospice care, 22:169-171
 - patient-physician communication, 22:169-171
- erectile dysfunction**
- cardiovascular disease, 7:55
 - pomegranate juice, 1:7
- estrogen therapy**
- gastroesophageal reflux, 19:148-149
- ethnicity**
- colon screening, 22:176
 - patient-physician relationship, 19:147-148
- exercise**, cognitive function, 19:151
- ezetimibe**
- cancer, 23:179-181
 - hyperlipidemia, 11:73-75
- F**
- fatigue**
- cardiovascular disease, 14:108-109
 - elderly, 24:188-189
 - mortality, 24:188-189
- fenofibrate**, diabetic retinopathy, 2:16
- fibromyalgia**, duloxetine, 13:101-102
- fish oils**, dyslipidemia, 18:139-140
- fluticasone**, COPD, 20:153-155; 18:144
- folic acid**
- cardiovascular disease, 13:100-101; 12:96
- formoterol**, COPD, 18:144
- fracture risk**, testosterone, 6:41-42
- G**
- gastroduodenal damage**
- aspirin-induced, 8:57-58
 - rabeprazole, 8:57-58
- gastroesophageal reflux**
- estrogen therapy, 19:148-149
- gender**, catheterization, 18:138-139
- genetic polymorphisms**
- C-reactive protein, 23:183
- glucocorticoid therapy**
- bone mineral density, 2:16
- glucose monitoring**
- accuracy of meters, 7:55
 - depression, 17:132-133
 - metrics, 17:135
 - Type 2 diabetes, 17:132-133
- gout**
- NSAIDs, 18:137-138
 - oral prednisolone, 13:103
 - steroids, 18:137-138
- H**
- heart failure**
- hospice care, 18:140-141
 - pulmonary cackles, 14:105-106
 - vitamin D, 23:178-179
 - whole grain cereal, 1:3-4
- hepatitis C**, screening, 9:68-69

HIV infection, etravirine, 4:30-31

homocysteine

cardiovascular disease, 20:159;
12:100-101; 12:96

honey, cough, 8:61

hormone replacement therapy

age-related skin changes, 19:151
breast cancer, 10:75-76
cardiovascular disease, 10:75-76

hospice care

caregiver bereavement, 22:169-171
caregiver support, 22:169-171
heart failure, 18:140-141
patient-physician communication,
22:169-171
predicting need, 18:140-141

H. pylori infection

sequential therapy, 13:99

human papillomavirus, vaccine, 21:165-166

Huntington's disease

chorea, 19:149-150
tetrabenazine, 19:149-150

hyperlipidemia

ezetimibe, 10:73-75
niacin/simvastatin, 6:37-38

hypertension

aliskiren and hydrochlorothiazide
tablets, 16:126-127
elderly, 11:87
nebivolol, 3:21-22
persistent, 7:51

hypertensive emergency

clevidipine, 17:133-134

hypogonadism, testosterone, 18:144

hypothyroidism

levothyroxine, 7:55
T3, 7:55

I

immunotherapy, sublingual, 14:112

influenza

complications, 10:76-77
elderly, 17:135
vaccine, 17:135

insulin therapy

beta-cell function, 22:176
Type 2 diabetes, 4:32

K

knee osteoarthritis

arthroscopy, 19:144-146
MRI, 20:159

L

levothyroxine, hypothyroidism, 7:55

lifestyle modification

cardiovascular disease, 18:141-143;

15:115-117

dyslipidemia, 18:139-140

lifting training/equipment

back pain, 6:42-43

linolenic acid

diabetic peripheral neuropathy, 4:32

lubiprostone

colonoscopy preparation, 22:173

lung cancer

emphysema, 24:185-186
smoking, 24:185-186

M

marijuana, withdrawal, 21:167

medication adherence

Medicare Part D, 11:87
rates, 15:119

Mediterranean diet

weight loss, 18:144

metabolic syndrome

continuous positive airway pressure,
24:192
sleep apnea, 24:192

methylaltraxone

opioid-induced constipation, 14:112

migraine

naproxen, 9:69-70
sumatriptan, 9:69-70

mortality

caffeine, 16:123-124
cardiovascular disease, 12:92-94
elderly, 24:188-189
fatigue, 24:188-189
testosterone in men, 2:11-13
vitamin D levels, 21:161-163
women, 12:92-94

MRI, knee osteoarthritis, 20:159

myocardial infarction

secondary prevention, 24:186-188

N

NSAIDs

back pain, 1:7
gout, 18:137-138
migraine, 9:69-70

nuts, diverticular disease, 17:131-132

O

obesity

abdominal, 12:92-94
cardiovascular disease, 15:115-117;
12:92-94
prostate cancer, 2:16
sexual dysfunction, 17:135
undiagnosed diabetes, 20:160
women, 12:92-94

occlusion therapy, warts, 5:33-34

omega-3 fatty acids

Crohn's disease, 11:81-82

opioid detoxification, duration, 23:183

osteoporosis

calcium supplementation, 4:25-26

P

patient-physician relationship

calcium supplementation recommenda-
tions, 15:121-122
communication, 22:169-171; 19:147-148
culture, 19:147-148
ethnicity, 19:147-148
patient implementation, 5:39

patient's socioeconomic status

physician's clinical decisions, 4:28-29

percutaneous coronary intervention

coronary artery disease, 18:141-143
coronary ischemia, 24:192

phenylketonuria, sapropterin, 2:14-15

physical decline, vitamin E, 5:39

pneumonia

antipsychotics, 11:83-85
elderly, 11:83-85

polyunsaturated fatty acids

chronic heart failure, 21:167

pomegranate juice, erectile dysfunction, 1:7

popcorn, diverticular disease, 17:131-132

pramlintide, weight loss, 19:151

prednisolone, gout, 13:103

pregabalin

diabetic peripheral neuropathic pain,
16:128

prevention

myocardial infarction, 24:186-188

prostate cancer

androgen deprivation therapy, 16:128
obesity, 2:16
PSA screening guidelines, 17:129-131

prucalopride, constipation, 14:112

PSA screening

clinical guidelines, 17:129-131

publication bias, antidepressant therapy, 5:39

pulmonary embolism

anticoagulant therapy, 3:19-20
multislice CT, 11:87
screening methods, 3:23
venous thromboembolism, 3:19-20

R

rabeprazole

aspirin-induced gastroduodenal damage,
8:57-58

radiation exposure

cancer, 5:35-36
CT scans, 5:35-36

radionuclide myocardial perfusion imaging

regadenoson, 11:85-86

red yeast rice, dyslipidemia, 18:139-140

reflexology

detrusor overactivity, 7:51-52

urinary frequency, 7:51-52

rosacea

small intestinal bacterial overgrowth,
15:114-115

rosiglitazone

diabetes, 12:96

fracture risk, 12:96

S

salmeterol, COPD, 20:153-155; 18:144

seasonal allergic rhinitis

ciclesonide, 1:4-5

seeds, diverticular disease, 17:131-132

sexual dysfunction

antidepressants, 16:124-126

obesity, 17:135

sildenafil, 16:124-126

women, 16:124-126

sildenafil, women, 16:124-126

sinusitis, antibiotics, 9:71

skin cancer, screening, 15:119

skin changes, hormone replacement, 19:151

sleep, weight gain, 12:89-90

sleep apnea

continuous positive airway pressure,
24:192; 2:9-11

metabolic syndrome, 24:192

sleep apnea, 2:9-11

small bowel resection, alvimopan, 12:94-95

small intestinal bacterial overgrowth

rosacea, 15:114-115

smoking

cessation, 9:65-66

emphysema, 24:185-186

lung age, 9:65-66

lung cancer, 24:185-186

risk, in women, 12:91-92

spinal manipulation, back pain, 1:7

statins, dyslipidemia, 18:139-140

STEMI, cardiac catheterization, 4:27-28

steroids, gout, 18:137-138

stroke

DASH diet, 9:66-68

risk, 8:60-61

transient ischemic attack, 8:60-61

suicide, female physicians, 3:20-21

T

testosterone

body composition, 18:144

bone mineral density, 18:144

fracture risk, 6:41-42

hypogonadism, 18:144

mortality in men, 2:11-13

supplementation in older men, 3:23

thiazolidinedione

coronary artery disease, 9:71

thrombocytopenia

romiplostim injection, 22:174-175

tiotropium

COPD, 21:163-165; 18:144

transient ischemic attacks

stroke risk, 8:60-61

vs transient neurologic attacks, 4:32

traumatic brain injury

microhemorrhages, 8:58-60

white matter disruption, 8:58-60

Type 2 diabetes

antidepressants, 8:64

beta-cell function, 13:103

breast size as predictor, 7:49-50

cardiovascular disease, 22:176; 20:156-159

carotid intima media thickness, 10:80

clinical guidelines, 24:177-178

colesevelam, 23:181-182

depression, 17:132-133

disease progression, 8:64

glucose monitoring, 17:132-133

insulin therapy, 4:32

intensive therapy, 6:48

obesity, 20:160

undiagnosed, 20:160

U

uric acid, cardiovascular disease, 24:192

urinary frequency, reflexology, 7:51-52

urinary tract infection

antibiotic choice, 3:17-19

V

vaccine

childhood, 15:117-118

duration of immunity, 1:2-3

HPV, 21:165-166

influenza, 17:135

venous thromboembolism

anticoagulant therapy, 3:19-20

cancer, 22:171-172

in-hospital deaths, 6:48

pulmonary thromboembolism, 3:19-20

vertebral fractures, risk factors, 3:23

vitamin B

cardiovascular disease, 13:100-101; 12:96

vitamin D

cardiovascular disease, 21:161-163

hip fractures, 23:178-179

mortality, 21:161-163

vitamin E

cardiovascular disease, 1:7

physical decline with aging, 5:39

W

warfarin

atrial fibrillation, 5:36-37

vs clopidogrel plus aspirin, 5:36-37

warts, occlusion therapy, 5:33-34

weight gain, sleep, 12:89-90

weight loss

low-carbohydrate diet, 18:144

low-fat diet, 18:144

Mediterranean diet, 18:144

pramlintide, 19:151

whole grain cereal, heart failure, 1:3-4

Pharmacology Update

(listed by trade name)

Avodart® plus Flomax®, 14:110-111

Bystolic™, 3:21-22

Cimzia®, 10:78-79

Cleviprex™, 17:133-134

Cymbalta®, 13:101-102

Entereg®, 12:94-95

Gardasil®, 21:165-166

Intelence™, 4:30-31

Kinrix™, 15:117

Kuvan™, 2:14-15

Lexiscan™, 11:85-86

Nplate™, 22:174-175

Omnaris™, 1:4-5

Pristiq™, 6:46-47

Rapaflo™, 24:190-191

Simcor®, 5:37-38

Somatulin® depot, 7:52-54

Tektura® HCT, 16:126-127

Treanda®, 8:62-63

Treximet™, 9:69-70

Welchol™, 23:181-182

Xenazine®, 19:149-150

ECG Review

A fast heart with chest pain, 21:168

A patient with chest pain, 19:152

A “pressure” phenomenon, 9:72

A “run of VT,” 7:56

A scooped ST tachycardia, 13:104

Atypical chest pain and an abnormal ECG, 1:8

AV block or blocked PACs? 17:136

Chest pain after bypass, 3:24

Having new chest pain or not? 23:184

Not just heart failure, 5:40

What are the 5 findings? 11:88

What’s there to worry about, 15:120